. "Letter Report." Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
TABLE 12 Incidence of Malaria from Randomization Up to 5 Months After the Last Dose of SP
Location, Country
Ifakara, Tanzania
Navrongo, Ghana
Manhiça, Mozambique
Kumasi, Ghana
Lambaréné, Gabon
Tamale, Ghana
Overall
Placebo
Episodes
158
1419
380
910
93
891
PYAR
288
1398
540
614
558
667
Incidence
0.55
1.01
0.70
1.48
0.17
1.34
IPTi with SP
Episodes
75
1068
269
770
82
711
PYAR
291
1403
546
620
577
668
Incidence
0.26
0.76
0.68
1.24
0.14
1.06
Efficacy (95% CI)
55 (27, 68)
25 (14, 35)
5 (−18, 24)
16 (8, 24)
13 (−26, 40)
21 (10, 30)
21 (11, 29)
p-value
<0.001
<0.001
0.64
<0.001
0.46
<0.001
<0.001
NOTE: PYAR: Person-years at risk
SOURCE: Compiled from data in the Report of the Statistical Working Group (IPTi Consortium, 2007b).
TABLE 13 Risk of Anemia from Randomization Up to 5 Months After the Last Dose of SP
Location, Country
Ifakara, Tanzania
Navrongo, Ghana
Manhiça, Mozambique
Kumasi, Ghana
Lambaréné, Gabon
Tamale, Ghana
Overall
Placebo
Episodes
31
234
87
316
110
347
Subjects
351
1225
748
535
507
599
Risk (%)
9
19
12
59
22
58
IPTi with SP
Episodes
22
215
103
291
86
319
Subjects
350
1221
755
535
504
600
Risk (%)
6
18
14
54
17
53
Efficacy (95% CI)
29 (−29, 58)
8 (−15, 26)
15 (−11, 35)
9 (−8, 22)
21 (−1, 39)
8 (−2, 17)
10 (4, 17)
p-value
0.21
0.47
0.24
0.31
0.06
0.10
0.003
NOTE: The committee used Stata to calculate the overall efficacy and its 95 percent confidence limit.
SOURCE: Data from the Report of the Statistical Working Group (IPTi Consortium, 2007b).
